博客

癌症

Onivyde: Offering Hope in Metastatic Pancreatic Cancer Treatment

Doctor consulting with patient with pancreatic cancer

Metastatic pancreatic cancer is a devastating disease with a low survival rate. However, there’s a promising chemotherapy drug for this condition — Onivyde (irinotecan liposome injection). It is used in combination with other chemotherapy medications to manage the targeted cancer.

与专家交谈

关于共付额援助
(877) 778-0318

As research into Onivyde continues, clinical trials are underway to assess its efficacy in treating other types of cancers.

Onivyde targets the enzyme topoisomerase I, which is essential for DNA replication in cancer cells. Its liposomal encapsulation helps to target cancer cells and reduce the reactions associated with the therapy. However, patients should be aware of the potential side effects of Onivyde and work closely with their healthcare provider to manage any symptoms.

In this article, we will delve into the mechanism of action, clinical trials, dosing, and potential side effects of Onivyde, as well as provide a comprehensive overview of what you can expect during treatment with this drug.

What Is Onivyde?

Onivyde, the brand name for irinotecan liposome injection, is a chemotherapy drug that treats pancreatic cancer, particularly metastatic pancreatic ductal adenocarcinoma. 

Onivyde was extensively evaluated in clinical trials. It showed remarkable efficacy and safety in treating metastatic pancreatic cancer. The NAPOLI-1 study, a key clinical trial that led to the approval of Onivyde by the US Food and Drug Administration, demonstrated that Onivyde, in combination with 5-fluorouracil and leucovorin, significantly improved overall and progression-free survival in patients who had previously received gemcitabine-based chemotherapy.

What Is Onivyde Used For?

Onivyde is a chemotherapy drug specifically used to treat metastatic pancreatic ductal adenocarcinoma of the pancreas.

The medication is administered in combination with other chemotherapy drugs, such as 5-fluorouracil (5-FU) and leucovorin. It is given as an intravenous infusion, meaning it is injected directly into a vein.

It’s important to note that Onivyde may not be suitable for all patients with metastatic pancreatic cancer, and treatment decisions should be made in consultation with a healthcare provider. 

Like other chemotherapy drugs, Onivyde may cause side effects, and you should discuss the potential risks and benefits of the drug with your healthcare provider.

How Does Onivyde Work?

Onivyde works by inhibiting the enzyme, topoisomerase I, which is necessary for DNA replication in cancer cells. By blocking this enzyme, Onivyde slows or stops the growth of cancer cells.

Onivyde contains irinotecan, which is an active substance in chemotherapy. However, Onivyde is unique from other forms of irinotecan because it is encapsulated in a liposome, a fat molecule. This helps the drug dissolve slowly and last longer in the body.

When Onivyde is administered through an intravenous infusion, the liposomes containing irinotecan are taken up by cancer cells. Once inside the cancer cells, the liposomes release the irinotecan, which then inhibits topoisomerase I. 

This, in turn, causes damage to the cancer cell’s DNA and prevents the cell from dividing and growing further. Onivyde may also affect healthy cells in the body, resulting in the reduction of blood cells. 

咨询化疗专家

获得化疗治疗援助
安排咨询

副作用

Man suffering from Onivyde side effects

Patients may experience some side effects while undergoing Onivyde therapy. These include:

常见副作用:

  • 疲劳
  • 腹泻
  • 恶心和呕吐
  • 食欲不振
  • 口腔溃疡
  • 发烧
  • Neutropenia (low white blood cell count)

Less Common But More Serious Side Effects:

  • Severe allergic reactions, including anaphylaxis
  • Severe diarrhea, which can lead to dehydration and electrolyte imbalances
  • Severe neutropenia, which can increase the risk of infection
  • Interstitial lung disease, a rare but serious condition that can cause shortness of breath and other respiratory symptoms

It’s important to remember that Onivyde may cause other reactions not listed here, so you should discuss all your concerns with your healthcare provider. 

Additionally, Onivyde may interact with other medications or health conditions, so patients should disclose their full medical history and all medications to their healthcare provider before starting treatment.

剂量信息

The dosing of Onivyde is determined by several factors, such as the patient’s body weight, age, medical history, and other medications they may be taking.

Onivyde is administered as an intravenous infusion, which means that it is given directly into a vein through a needle or catheter. It should only be administered by a medical personnel that is highly experienced in infusing cancer drugs. It’s advisable that you receive this therapy in an infusion center or hospital to avoid any complications. The people at the facility should also be knowledgeable about the risks and possible drug interactions. 

For the treatment of metastatic pancreatic cancer in combination with 5-fluorouracil (5-FU) and leucovorin, the recommended dose of Onivyde is 70 mg/m². This dose is given as an intravenous infusion over a period of 90 minutes once every 2 weeks until cancer progression or unacceptable side effects  

Your healthcare provider may adjust the dose based on your response to treatment. It is critical to report any side effects or unusual reactions to your healthcare provider as some side effects may require immediate medical attention.

防范措施

  1. Before starting treatment with Onivyde, patients should discuss their medical history and any medications they are taking with their healthcare provider.
  2. Patients should inform their healthcare provider if they are pregnant or planning to become pregnant, as Onivyde may harm a developing fetus. Although there are no confirmed cases, it’s not advisable to take Onivyde while pregnant. Use contraceptives during therapy and for one month after your final dose.
  3. You should not take Onivyde if you have interstitial lung disease.
  4. It’s not advisable to continue the medication if you experience hypersensitivity to irinotecan HCI or Onivyde. The medication can cause severe hypersensitivity reactions. 
  5. Patients should also be aware that Onivyde may cause fatigue, and they should avoid activities that require alertness until they know how the drug affects them.
  6. It is important to follow all instructions provided by your healthcare provider. Do not stop your treatment without first consulting your healthcare provider.

获得化疗共付额援助

化疗经济援助
(877) 778-0318

成本

The cost of Onivyde is determined by various factors such as dosage, frequency of administration, patient location, and insurance coverage. Patients may be able to obtain Onivyde at a lower cost if they have insurance coverage or are eligible for financial assistance programs. 

Keep in mind that this medication is not readily accessible over-the-counter. A  prescription from your doctor is required. You can also discuss the cost of Onivyde with your healthcare provider and insurance company to explore options for financial assistance if necessary.

此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
医学审核人 Christine Leduc 博士,药学博士

Christine Leduc 博士,药学博士,在加州尔湾市出生长大。她就读于中西部大学,并以优异成绩毕业。她工作中最有成就感的部分是建议改变生活方式,教育患者了解药物的药理作用,以及指导未来的药剂师。她的专业领域是客户服务和专科药物知识。她曾在服务行业工作,积累了理解患者需求所需的客户服务技能。Leduc 博士目前正在指导马歇尔·B·凯彻姆大学、堪萨斯大学和中西部大学的学生。闲暇时,她喜欢旅行、烘焙和园艺。 参见作者简介

联系我们

使用下方符合 HIPAA 标准的表格申请续药。如果您对药物或用药方法有任何疑问,请访问“联系我们”页面或致电 (877) 778-0318.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知

zh_CNChinese